0001759655-26-000064 | 10-Q | XBRL Viewer

Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2026

Schedule of Reconciliation of Net Income Available to Common Stockholders and Number of Shares in Calculation of Basic and Diluted Earnings Income Per Share

A reconciliation of net income available to common stockholders and the number of shares in the calculation of basic and diluted earnings income per share was calculated as follows:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(Dollars in thousands, except for share and per share amounts)	2026		2025		2026		2025
Net income attributable to Privia Health Group, Inc. common stockholders	$	9,048	$	2,687	$	12,112	$	6,907
Weighted average common shares outstanding - basic	126,121,426		122,132,245		125,142,415		121,370,949
Weighted average common share outstanding - diluted	131,827,233		128,447,069		131,355,421		128,149,252
Earnings per share attributable to Privia Health Group, Inc. common stockholders – basic	$	0.07	$	0.02	$	0.10	$	0.06
Earnings per share attributable to Privia Health Group, Inc. common stockholders – diluted	$	0.07	$	0.02	$	0.09	$	0.05

Schedule of Weighted-Average Anti-Dilutive Shares Outstanding Were Excluded From the Computation of Diluted Loss Per Share

Below are the weighted-average diluted shares outstanding that were excluded from the computation of diluted loss per share attributable to common stockholders for the period presented because they were anti-dilutive:


	Six Months Ended June 30,
	2026	2025
Weighted-average antidilutive shares outstanding	4,116,262	4,931,666

Goodwill and Intangible Assets, Net - Schedule of Remaining Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Intangible Asset, Goodwill and Other [Abstract]
Remainder of 2026	$ 6,724
2027	13,449
2028	13,449
2029	13,449
2030	13,449
Thereafter	158,134
Total	$ 218,654	$ 215,919

Revenue Recognition

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Revenue Recognition

The following table presents our revenues disaggregated by source:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
(Dollars in thousands)	2026		2025		2026		2025
FFS-patient care	$	412,640	$	331,464	$	803,773	$	643,225
FFS-administrative services	33,222		35,116		64,625		67,371
Capitated revenue	95,150		75,511		181,298		146,201
Shared savings	68,920		60,021		143,883		107,933
Care management fees (PMPM)	20,733		16,919		38,600		32,121
Other revenue	1,965		2,122		4,298		4,399
Total revenue	$	632,630	$	521,153	$	1,236,477	$	1,001,250

Fee-for-service (“FFS”) patient care is primarily generated from third-party payers with which the Company has established contractual billing arrangements. The following table presents the approximate percentages by source of net revenue received for healthcare services we provided for the periods indicated:


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Commercial insurers	72	%	71	%	71	%	70	%
Government payers	13	%	14	%	13	%	14	%
Patient	15	%	15	%	16	%	16	%
	100	%	100	%	100	%	100	%

FFS-administrative services revenue is earned through the Company’s MSA with Non-Owned Medical Groups primarily based on a fixed percentage of net collections on patient care generated by those medical groups.

Value Based Care (“VBC”) revenue is primarily earned through contracts for capitated revenue, shared savings and care management fees (“PMPM”). Capitated revenue is generated through what is typically known as an “at-risk contract.” At-risk capitation refers to a model in which the Company receives a fixed monthly payment from the third-party payer in exchange for providing healthcare services to attributed beneficiaries. The Company is responsible for providing or paying for the cost of healthcare services required by those attributed beneficiaries for a set of services. Capitated revenue is recorded at the total amount gross in revenues because the Company is acting as a principal in arranging for, providing, and controlling the managed healthcare services provided to the Attributed Lives (as defined herein). Shared savings revenue and PMPM are generated through contracts with large commercial payer organizations and the U.S. Federal Government.

Contract Asset

The Company has the following contract assets:


(Dollars in thousands)	June 30, 2026		December 31, 2025
Balances for contracts with customers
Accounts receivable	$	574,160	$	400,902

Remaining Performance Obligations

As our performance obligations relate to contracts with a duration of one year or less, the Company elected the optional exemption in ASC 606-10-50-14(a). Therefore, the Company is not required to disclose the transaction price for the remaining performance obligations at the end of the reporting period or when the Company expects to recognize revenue. The Company has minimal

unsatisfied performance obligations at the end of the reporting period as our patients typically are under no obligation to continue receiving services at our facilities.

Stockholders’ Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 19,396	$ 18,849	$ 41,317	$ 36,639
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	11,519	10,138	24,927	20,755
Location, Statement of Income, Balance [Axis]: us-gaap:SellingAndMarketingExpense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	1,677	1,488	3,467	2,690
Location, Statement of Income, Balance [Axis]: prva:CostOfPlatform
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 6,200	$ 7,223	$ 12,923	$ 13,194

Debt (Details) - Revolving Credit Agreement - Line of Credit - USD ($)	May 06, 2026	Nov. 16, 2023	Jun. 30, 2026
Minimum \| Base Rate
Line of Credit Facility [Line Items]
Basis spread on variable rate (as a percent)	0.25%
Minimum \| Secured Overnight Financing Rate (SOFR)
Line of Credit Facility [Line Items]
Basis spread on variable rate (as a percent)	1.25%
Maximum \| Base Rate
Line of Credit Facility [Line Items]
Basis spread on variable rate (as a percent)	0.75%
Maximum \| Secured Overnight Financing Rate (SOFR)
Line of Credit Facility [Line Items]
Basis spread on variable rate (as a percent)	1.75%
Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 250,000,000	$ 125,000,000
Debt instrument, term (in years)		5 years
Unused capacity, commitment fee percentage		0.20%
Line of credit outstanding			$ 0
Revolving Credit Facility \| Minimum
Line of Credit Facility [Line Items]
Unused capacity, commitment fee percentage		0.20%
Revolving Credit Facility \| Maximum
Line of Credit Facility [Line Items]
Unused capacity, commitment fee percentage		0.30%

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	$ 254,276	$ 245,195
Less accumulated amortization	35,622	29,276
Total	218,654	215,919
Trade names
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	4,600	4,600
Less accumulated amortization	2,722	2,607
Consumer customer relationships
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	3,100	3,100
Less accumulated amortization	2,796	2,783
Service Agreements \| Management service agreement
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	2,200	2,200
Less accumulated amortization	1,478	1,409
Service Agreements \| MSO service agreement
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	51,800	51,800
Less accumulated amortization	11,717	10,483
Physician network \| Physician network
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	19,814	16,052
Less accumulated amortization	2,640	2,016
Payer contracts
Intangible Asset, Finite-Lived [Line Items]
Finite lived intangible assets, gross	172,762	167,443
Less accumulated amortization	$ 14,269	$ 9,978

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Payables and Accruals [Abstract]
Accounts payable	$ 8,494	$ 7,973
Accrued employee compensation and benefits	21,283	33,552
Other accrued expenses	61,233	55,279
Total accounts payable and accrued expenses	$ 91,010	$ 96,804

Organization and Summary of Significant Accounting Policies (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($) market company	Dec. 31, 2025 USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of markets in which entity operates \| market	17
MSO, ownership percentage (as a percent)	100.00%
Number of MSOs where the company is at least the majority owner \| company	4
Current assets	$ 1,025,266	$ 911,001
Current liabilities	634,444	568,520
Variable Interest Entity, Primary Beneficiary \| PMG West Texas And PMG-TN
Subsidiary, Sale of Stock [Line Items]
Current assets	19,500	18,900
Current liabilities	$ 19,500	$ 18,900

Organization and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies Organization Privia Health Group, Inc. (“Privia Health,” “Privia,” “we,” “our” or the “Company”) is a technology-driven, national physician-enablement company that collaborates with physician practices, health plans, and health systems to achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers. The Company pursues the quadruple aim by entering markets and organizing existing physicians and non-physician clinicians into a unique practice model that combines the advantages of a partnership in a large regional medical group (each, a “Medical Group” and together, “Medical Groups”) with significant provider autonomy for physicians (collectively, “Privia Physicians”) and non-physician clinicians (collectively “Privia Clinicians” and, together with the Privia Physicians, the “Privia Providers”) joining the Company’s Medical Groups. Privia Physicians join the Medical Groups in their geographic market as an owner of the Medical Group. As of June 30, 2026, Privia operated Medical Groups in seventeen markets: (1) the Mid-Atlantic Region (states of Virginia, Maryland and the District of Columbia); (2) Georgia; (3) the Gulf Coast Region (Houston-San Antonio-Austin, Texas); (4) North Texas (Dallas/Fort Worth, Texas); (5) West Texas (Abilene, Texas); (6) Central Florida; (7) Tennessee; (8) California; (9) Montana; (10) Ohio; (11) North Carolina; (12) Connecticut; (13) Washington state; (14) South Carolina; (15) Indiana; (16) Arizona; and (17) New Jersey. The Company also provides management and administrative services through local management services organizations (each, an “MSO”) to the Medical Groups through a Management Services Agreement (“MSA”) in each market. The Company owns 100% of all MSOs, except four where the Company is at least the majority owner. Basis of Presentation The condensed consolidated financial statements are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its subsidiaries. Amounts shown on the condensed consolidated statements of operations within the operating expense categories of provider expense, cost of platform, selling and marketing, and general and administrative are recorded exclusive of depreciation and amortization. All significant intercompany transactions are eliminated in consolidation. The results of operations for the three and six months ended June 30, 2026, are not indicative of the results to be expected for the full fiscal year ending December 31, 2026. The condensed consolidated balance sheet at December 31, 2025 was derived from audited annual financial statements but does not contain all disclosures required by GAAP. In the opinion of management, all adjustments (consisting of only normal and recurring adjustments) considered necessary for a fair statement have been included. The Company described its significant accounting policies in Note 1 of the notes to consolidated financial statements for the year ended December 31, 2025 in the Annual Report on Form 10-K. During the three and six months ended June 30, 2026, there were no significant changes to those accounting policies and estimates. Variable Interest Entities Management evaluates the Company’s ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company has relationships with medical groups in which the Company has no ownership interests, which are either (a) owned 100% by Privia Physicians (each, a “Non-Owned Medical Group” and collectively, “Non-Owned Medical Groups”) or (b) majority owned, indirectly through a professional entity by a licensed physician holding a Privia leadership position (each, a “Friendly Medical Group” and collectively, “Friendly Medical Groups”). Each of our Medical Groups (e.g., Owned Medical Groups, Non-Owned Medical Groups and Friendly Medical Groups) contracts with the Privia Physician’s historic practice entity, which no longer furnishes healthcare services (the “Affiliated Practice”) whereby the Affiliated Practice provides certain subcontracted services to the Medical Groups to allow the Medical Group to operate at the practice location. The Company evaluated its relationship with (a) Non-Owned Medical Groups and their Affiliated Practices, (b) Friendly Medical Groups and their Affiliated Practices, and (c) Affiliated Practices associated with Owned Medical Groups to determine if any of these entities should be subject to consolidation. The Company does not have ownership interest in any Affiliated Practices (whether those of Owned Medical Groups, Non-Owned Medical Groups or Friendly Medical Groups); nor does the Company have an ownership in Non-Owned Medical Groups. The Physician Member Services Agreement (“PMSA”) and support services agreement (“SSA”) entered by Non-Owned Medical Groups and Friendly Medical Groups with their Privia Physician members and the Affiliated Practices are not contractual relationships within Privia’s legal structure. The only contractual relationship between Privia and Non-Owned Medical Groups is established through the MSA. For Friendly Medical Groups, in addition to the MSA, the Company has a contractual relationship, evidenced by a restriction agreement (each a “Restriction Agreement”) with licensed physicians holding a Privia leadership position (“Nominee Physicians”) and their respective Friendly Medical Groups. Management has determined, based on the provisions of the MSAs between the Company and Non-Owned Medical Groups, and after considering the requirements of Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), the Company is not required to consolidate the financial position or results of operations of the Affiliated Practices associated with Owned Medical Groups; nor is it required to consolidate the financial position or results of operations of Non-Owned Medical Groups (and, therefore, the Company is not required to consolidate the Affiliated Practices of the Non-Owned Medical Groups). However, management has determined, based on the provisions of the Restriction Agreement on the Nominee Physician (“Friendly PC”), the governing documents of the Friendly Medical Groups, and after considering the requirements of ASC 810, that the Company should consolidate the financial position and results of operations of the Friendly Medical Groups and the Friendly PCs. ASC 810 requires the Company to consolidate the financial position, results of operations and cash flows of a Non-Owned Medical Group affiliated by means of a service agreement if the Non-Owned Medical Group is a VIE and the Company is its primary beneficiary. An Affiliated Practice would be considered a VIE if (a) it is thinly capitalized (i.e., the equity is not sufficient to fund the Non-Owned Medical Group’s activities without additional subordinated financial support) or (b) the equity holders of the Non-Owned Medical Group as a group have one of the following four characteristics: (i) lack the power to direct the activities that most significantly affect the Non-Owned Medical Group’s economic performance, (ii) possess non-substantive voting rights, (iii) lack the obligation to absorb the Non-Owned Medical Group’s expected losses, or (iv) lack the right to receive the Non-Owned Medical Group’s expected residual returns. The characteristics of both (a) and (b) do not exist and as such the Non-Owned Medical Groups do not represent VIEs. Accordingly, the Company has not consolidated the financial position, results of operations or cash flows of the Non-Owned Medical Groups that are affiliated with the Company by means of a service agreement for the three months ended June 30, 2026 and 2025. Each time that it enters into a new service agreement or enters into a material amendment to an existing service agreement, the Company considers whether the terms of that agreement or amendment would change the elements it considers in accordance with the VIE guidance. The same analysis was performed for the Affiliated Practices of Owned Medical Groups, which have contractual relationships with Privia through the SSA, and the Company determined they do not represent VIEs as they do not meet the criteria in ASC 810 for similar reasons as those outlined above. The Company, however, does meet the criteria for consolidation of the Nominee PCs and the Friendly Medical Groups based on the discussion above. Privia Medical Group – West Texas, PLLC, (“PMG West Texas”) is a physician-owned Medical Group, with PMG West Texas Holdings, PLLC (“Friendly WTX PC”), a Texas professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests and having governance and control rights via the governing documents of PMG West Texas. The Company has a contractual relationship with Friendly WTX PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (ii) and (iv) and, as such, PMG West Texas and Friendly WTX PC do represent VIEs and are consolidated as they do meet the criteria in ASC 810. Privia Medical Group Tennessee, PLLC (“PMG-TN”) is a physician-owned Medical Group, with PMG-TN Physicians, PLLC (“Friendly TN PC”), a Tennessee professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests therein and having governance and control rights via the governing documents of PMG-TN. Again, the same analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (ii) and (iv) and, as such, PMG-TN and Friendly TN PC do represent VIEs as they do meet the criteria in ASC 810. Privia Medical Group Washington, PLLC, (“PMG WA”) is a physician-owned Medical Group, with PMG Washington Holdings, PLLC (“Friendly WA PC”), a Washington professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests and having governance and control rights via the governing documents of PMG WA. The Company has a contractual relationship with Friendly WA PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG WA and Friendly WA PC do represent VIEs and are consolidated as they do meet the criteria in ASC 810. Privia Medical Group South Carolina, LLC, (“PMG SC”) is a physician-owned Medical Group, with PMG South Carolina Holdings, PLLC (“Friendly SC PC”), a South Carolina professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests and having governance and control rights via the governing documents of PMG SC. The Company has a contractual relationship with Friendly SC PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG SC and Friendly SC PC represent VIEs and are consolidated as they meet the criteria in ASC 810. Privia Medical Group Indiana, LLC, (“PMG IN”) is a physician-owned Medical Group, with PMG Holdings Indiana, LLC, (“Friendly IN PC”), an Indiana professional limited liability company entirely owned by a licensed physician with a leadership role in the Company, owning majority membership interests and having governance and control rights via the governing documents of PMG IN. The Company has a contractual relationship with Friendly IN PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG IN and Friendly IN PC represent VIEs and are consolidated as they meet the criteria in ASC 810. Privia Medical Group Arizona, PLLC (“PMG-AZ”) is an Owned Medical Group, with the Company owning a majority of the membership interests and having governance and control rights through the governing documents of PMG-AZ. The VIE analysis was performed, and the Company determined that characteristic (a) exists, and, as such, PMG-AZ does represent a VIE and is consolidated as it does meet the criteria in ASC 810. Privia Medical Group New Jersey, LLC (“PMG-NJ”) is a physician-owned Medical Group, with PMGNJ Hold Co, P.C., (“Friendly NJ PC”), a New Jersey professional corporation entirely owned by a licensed physician with a leadership role in the Company, owning majority membership interests and having governance and control rights via the governing documents of PMG-NJ. The Company has a contractual relationship with Friendly NJ PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG-NJ and Friendly NJ PC represent VIEs and are consolidated as they meet the criteria in ASC 810. The aggregated carrying value of the Company’s VIEs for both the current assets and liabilities included in the consolidated balance sheets after elimination of intercompany transactions was $19.5 million as of June 30, 2026 and $18.9 million as of December 31, 2025. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. On an on-going basis, the Company evaluates significant estimates and assumptions, including, but not limited to, provider liability, revenue recognition, stock-based compensation, estimated useful lives of assets, intangible assets subject to amortization, the fair value of assets acquired and liabilities assumed in business combinations, and the provision for income taxes. These estimates are based on historical experience, current conditions, and other assumptions that management believes are reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are reviewed and updated as new information becomes available, additional experience is gained, future events occur, or the Company’s operating environment changes. Recently Adopted Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures (“ASU 2023-09”). The amendments require (i) enhanced disclosures in connection with an entity’s effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendment is effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 for the annual period ending December 31, 2025 on a prospective basis. In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in a Variable-Interest Entity. The amendment clarifies the guidance when an entity involved in an acquisition transaction effected primarily by exchanging equity interests and the legal acquiree is a VIE that meets the definition of a business. Entities must identify the accounting acquirer using the factors in ASC 805-10-55-12 through 55-15, rather than relying solely on the VIE consolidation model. The amendment is effective for annual reporting periods beginning after December 15, 2026, including interim periods within the fiscal years and applied prospectively to acquisitions after the adoption date. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements or related disclosures. Recently Issued Accounting Pronouncements Pending Adoption In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (“DISE”) and in January 2025, issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure, which clarified the effective date of ASU 2024-03. The amendment requires disclosures about the nature of expenses included in the income statement, such as purchases of inventory, employee compensation and depreciation. The amendment is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact of ASU 2024-03 on its financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The amendment provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendment is effective for annual reporting periods beginning after December 15, 2027, including interim periods within the fiscal years, with early adoption permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-12, Codification Improvements (“Codification”), which addresses suggestions received from stakeholders on the Codification and makes other incremental improvements to GAAP. This evergreen project facilitates Codification updates for a broad range of topics arising from technical corrections, the unintended application of the Codification, clarifications, and other minor improvements. The amendment is effective for annual reporting periods beginning after December 15, 2026, including interim periods within the fiscal years, with early adoption permitted. The Company does not expect ASU 2025-12 to have a material impact on its financial statements and related disclosures.

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 7,017	$ 2,456	$ 12,617	$ 4,559
Effective income tax rate (as a percent)			48.40%	32.80%

Stockholders’ Equity - Schedule of RSU and PSU Activity (Details)	6 Months Ended
	Jun. 30, 2026 $ / shares shares
Restricted Stock Units (RSUs)
Number of Shares
Beginning balance (in shares) \| shares	3,847,183
Granted (in shares) \| shares	2,435,096
Vested (in shares) \| shares	(1,695,847)
Forfeited (in shares) \| shares	(98,413)
Ending balance (in shares) \| shares	4,488,019
Grant Date Fair Value
Beginning balance (in dollars per share) \| $ / shares	$ 24.39
Granted (in dollars per share) \| $ / shares	22.52
Vested (in dollars per share) \| $ / shares	24.68
Forfeited (in dollars per share) \| $ / shares	23.35
Ending balance (in dollars per share) \| $ / shares	$ 23.29
Performance Stock Units (PSUs)
Number of Shares
Beginning balance (in shares) \| shares	2,443,331
Granted (in shares) \| shares	974,645
Vested (in shares) \| shares	(621,253)
Forfeited (in shares) \| shares	(21,535)
Ending balance (in shares) \| shares	2,775,188
Grant Date Fair Value
Beginning balance (in dollars per share) \| $ / shares	$ 26.41
Granted (in dollars per share) \| $ / shares	22.47
Vested (in dollars per share) \| $ / shares	27.99
Forfeited (in dollars per share) \| $ / shares	23.88
Ending balance (in dollars per share) \| $ / shares	$ 24.97

Debt	6 Months Ended
Debt	Jun. 30, 2026
Debt Disclosure [Abstract]
Debt	Debt On November 16, 2023, Privia Health Group, Inc., PH Group Holdings Corp., and Privia Health, LLC, as borrower, (collectively, the “Privia Parties”) entered into a credit agreement (the “Revolving Credit Agreement”) with Wells Fargo Bank, National Association, as issuing lender, and certain other lenders, pursuant to which the Privia Parties established a $125 million five-year senior secured revolving credit facility (the “Revolving Credit Facility”). On May 6, 2026 the Company entered into an amendment to the Revolving Credit Agreement (the “First Amendment”). The First Amendment increases the aggregate amount available under the Revolving Credit Agreement to $250 million and extends the term through 2031. The First Amendment bears interest at either i) a base rate, as defined in the Revolving Credit Agreement, plus an applicable margin ranging from 0.25% to 0.75%, or ii) SOFR, as defined in the Revolving Credit Agreement, plus an applicable margin that ranges from 1.25% to 1.75%, depending on the consolidated total leverage ratio, as defined in the Revolving Credit Agreement. The Revolving Credit Agreement includes a commitment fee on the unused Revolving Credit Facility that ranges from 0.20% to 0.30% (0.20% per annum at year end) depending on the consolidated leverage ratio. The facility generally may be used for capital expenditures, expenses related to transactions and general corporate purposes. The Revolving Credit Agreement contains customary affirmative, negative and financial covenants, and events of default. The occurrence of an event of default under the Revolving Credit Agreement may cause the unpaid principal and accrued interest, and all other obligations under the Revolving Credit Agreement, to become immediately due and payable. As of June 30, 2026, no amounts were outstanding under the Revolving Credit Facility. Substantially all of the Company’s real and personal property serve as collateral under this agreement.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026 shares
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
Parth Mehrotra [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On May 13, 2026, Parth Mehrotra, the Company’s Chief Executive Officer and a member of the Board, terminated a trading plan for the sale of securities intended to satisfy the affirmative defense conditions of Rule 10b5-1 of the Exchange Act, which he adopted on May 27, 2025 and was scheduled to end on December 31, 2026, with a duration of approximately sixteen months (“the Terminated Mehrotra Plan”). The aggregate amount of securities that could have been sold under the Terminated Mehrotra Plan was 685,270.
Name	Parth Mehrotra
Title	Chief Executive Officer and a member of the Board
Rule 10b5-1 Arrangement Terminated	true
Termination Date	May 13, 2026
Aggregate Available	685,270

Business Combinations - Schedule of Preliminary Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2026	May 19, 2026	Dec. 31, 2025	Apr. 30, 2025
Identifiable intangible assets:
Goodwill	$ 215,789		$ 209,842
PMG-NJ
Business Combination [Line Items]
Accounts receivable		$ 880
Identifiable intangible assets:
Goodwill		5,947
Deferred tax liability		(2,328)
Provider liability		(880)
Total acquired net assets		12,700
PMG-NJ \| Payer contract and physician network intangibles
Identifiable intangible assets:
Payer contract and physician network intangibles		$ 9,081
PMG AZ
Business Combination [Line Items]
Cash				$ 5,942
Accounts receivable				6,319
Identifiable intangible assets:
Payer contract and physician network intangibles				64,400
Goodwill				43,838
Deferred tax liability				(13,238)
Provider liability				(12,261)
Total acquired net assets				$ 95,000

Concentration of Credit and Revenue Risk - Narrative (Details)	6 Months Ended
	Jun. 30, 2026 institution
Risks and Uncertainties [Abstract]
Number of institutions in which company holds its cash and cash equivalents	2

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net income	$ 13,444	$ 9,334
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation	291	415
Amortization of intangibles	6,346	4,069
Stock-based compensation	41,317	36,639
Deferred income taxes, net	3,683	2,671
Changes in asset and liabilities:
Accounts receivable, net	(172,378)	(121,497)
Prepaid expenses and other current assets	(8,492)	(21,344)
Other non-current assets and right-of-use assets	1,472	1,056
Accounts payable and accrued expenses	(5,794)	(7,687)
Provider liability	70,972	81,185
Operating lease liabilities	(1,032)	(778)
Other long-term liabilities	1,806	(153)
Net cash used in operating activities	(48,365)	(16,090)
Cash from investing activities
Business acquisitions, net of cash acquired	(11,430)	(89,058)
Other	(59)	0
Net cash used in investing activities	(11,489)	(89,058)
Cash flows from financing activities
Proceeds from exercised stock options	1,600	4,126
Proceeds from non-controlling interest	2,213	0
Repurchase of non-controlling interest	(11,444)	0
Net cash (used in) provided by financing activities	(7,631)	4,126
Net decrease in cash and cash equivalents	(67,485)	(101,022)
Cash and cash equivalents at beginning of period	479,685	491,149
Cash and cash equivalents at end of period	412,200	390,127
Supplemental disclosure of cash flow information:
Interest paid	162	124
Income taxes paid	10,656	5,771
Supplemental disclosure of non-cash operating activities:
Lease liabilities obtained in exchange for right-of-use assets	234	1,832
Contingent consideration payable	$ 1,270	$ 0

Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($) $ in Thousands	Total	Total Stockholders’ Equity attributable to Privia Health Group, Inc.	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2024			120,309,346
Beginning balance at Dec. 31, 2024	$ 683,447	$ 635,183	$ 1,203	$ 813,209	$ (179,229)	$ 48,264
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)			1,081,968
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	2,243	2,243	$ 11	2,232
Stock-based compensation expense	17,790	17,790		17,790
Net income	6,046	4,220			4,220	1,826
Ending balance (in shares) at Mar. 31, 2025			121,391,314
Ending balance at Mar. 31, 2025	709,526	659,436	$ 1,214	833,231	(175,009)	50,090
Beginning balance (in shares) at Dec. 31, 2024			120,309,346
Beginning balance at Dec. 31, 2024	683,447	635,183	$ 1,203	813,209	(179,229)	48,264
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	9,334
Ending balance (in shares) at Jun. 30, 2025			122,673,254
Ending balance at Jun. 30, 2025	733,546	682,855	$ 1,227	853,950	(172,322)	50,691
Beginning balance (in shares) at Mar. 31, 2025			121,391,314
Beginning balance at Mar. 31, 2025	709,526	659,436	$ 1,214	833,231	(175,009)	50,090
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)			1,281,940
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	1,883	1,883	$ 13	1,870
Stock-based compensation expense	18,849	18,849		18,849
Net income	3,288	2,687			2,687	601
Ending balance (in shares) at Jun. 30, 2025			122,673,254
Ending balance at Jun. 30, 2025	$ 733,546	682,855	$ 1,227	853,950	(172,322)	50,691
Beginning balance (in shares) at Dec. 31, 2025	123,604,576		123,604,576
Beginning balance at Dec. 31, 2025	$ 790,943	737,217	$ 1,236	892,291	(156,310)	53,726
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)			2,084,429
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	774	774	$ 21	753
Stock-based compensation expense	21,921	21,921		21,921
Repurchase of non-controlling interest	(11,444)	(9,917)		(9,917)		(1,527)
Net income	3,710	3,064			3,064	646
Ending balance (in shares) at Mar. 31, 2026			125,689,005
Ending balance at Mar. 31, 2026	$ 805,904	753,059	$ 1,257	905,048	(153,246)	52,845
Beginning balance (in shares) at Dec. 31, 2025	123,604,576		123,604,576
Beginning balance at Dec. 31, 2025	$ 790,943	737,217	$ 1,236	892,291	(156,310)	53,726
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 13,444
Ending balance (in shares) at Jun. 30, 2026	126,289,983		126,289,983
Ending balance at Jun. 30, 2026	$ 838,073	782,329	$ 1,263	925,264	(144,198)	55,744
Beginning balance (in shares) at Mar. 31, 2026			125,689,005
Beginning balance at Mar. 31, 2026	805,904	753,059	$ 1,257	905,048	(153,246)	52,845
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options and vesting of restricted stock units (in shares)			600,978
Issuance of common stock upon exercise of stock options and vesting of restricted stock units	826	826	$ 6	820
Stock-based compensation expense	19,396	19,396		19,396
Contributed non-controlling interest	2,213					2,213
Net income	$ 9,734	9,048			9,048	686
Ending balance (in shares) at Jun. 30, 2026	126,289,983		126,289,983
Ending balance at Jun. 30, 2026	$ 838,073	$ 782,329	$ 1,263	$ 925,264	$ (144,198)	$ 55,744

Provider Liability (Details) - USD ($) $ in Thousands	6 Months Ended
Provider Liability (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	$ 469,516
Claims paid
Balance, end of period	541,368
At-Risk Capitation Arrangements
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	78,989	$ 66,355
Incurred health care costs
Current year	175,800	144,840
Prior years	(13,225)	(555)
Total claims incurred	162,575	144,285
Claims paid
Current year	(83,892)	(63,025)
Prior years	(58,695)	(47,959)
Total claims paid	(142,587)	(110,984)
Balance, end of period	$ 98,977	$ 99,656

Business Combinations - Schedule of Cash Paid for Acquisition (Details) - USD ($) $ in Thousands		1 Months Ended
	May 19, 2026	Apr. 30, 2025	Jun. 30, 2026	Dec. 31, 2025
Business Combination [Line Items]
Goodwill			$ 215,789	$ 209,842
PMG-NJ
Business Combination [Line Items]
Fair value of assets acquired	$ 9,961
Goodwill	5,947
Deferred tax liability	(2,328)
Provider liability	(880)
Contingent consideration payable	(1,270)
Net cash paid for acquisition	$ 11,430
PMG AZ
Business Combination [Line Items]
Fair value of assets acquired		$ 70,719
Goodwill		43,838
Deferred tax liability		(13,238)
Provider liability		(12,261)
Net cash paid for acquisition		89,058
Cash acquired		$ 5,900

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) and include the accounts of the Company and its subsidiaries. Amounts shown on the condensed consolidated statements of operations within the operating expense categories of provider expense, cost of platform, selling and marketing, and general and administrative are recorded exclusive of depreciation and amortization.
Consolidation	All significant intercompany transactions are eliminated in consolidation.
Variable Interest Entities	Variable Interest Entities Management evaluates the Company’s ownership, contractual, and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment and assumptions based on available historical information, among other factors. If the Company determines that an entity in which it holds a contractual, or ownership, interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its consolidated financial statements. The primary beneficiary of a VIE is the party that meets both of the following criteria: (i) has the power to make decisions that most significantly affect the economic performance of the VIE; and (ii) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively. The Company has relationships with medical groups in which the Company has no ownership interests, which are either (a) owned 100% by Privia Physicians (each, a “Non-Owned Medical Group” and collectively, “Non-Owned Medical Groups”) or (b) majority owned, indirectly through a professional entity by a licensed physician holding a Privia leadership position (each, a “Friendly Medical Group” and collectively, “Friendly Medical Groups”). Each of our Medical Groups (e.g., Owned Medical Groups, Non-Owned Medical Groups and Friendly Medical Groups) contracts with the Privia Physician’s historic practice entity, which no longer furnishes healthcare services (the “Affiliated Practice”) whereby the Affiliated Practice provides certain subcontracted services to the Medical Groups to allow the Medical Group to operate at the practice location. The Company evaluated its relationship with (a) Non-Owned Medical Groups and their Affiliated Practices, (b) Friendly Medical Groups and their Affiliated Practices, and (c) Affiliated Practices associated with Owned Medical Groups to determine if any of these entities should be subject to consolidation. The Company does not have ownership interest in any Affiliated Practices (whether those of Owned Medical Groups, Non-Owned Medical Groups or Friendly Medical Groups); nor does the Company have an ownership in Non-Owned Medical Groups. The Physician Member Services Agreement (“PMSA”) and support services agreement (“SSA”) entered by Non-Owned Medical Groups and Friendly Medical Groups with their Privia Physician members and the Affiliated Practices are not contractual relationships within Privia’s legal structure. The only contractual relationship between Privia and Non-Owned Medical Groups is established through the MSA. For Friendly Medical Groups, in addition to the MSA, the Company has a contractual relationship, evidenced by a restriction agreement (each a “Restriction Agreement”) with licensed physicians holding a Privia leadership position (“Nominee Physicians”) and their respective Friendly Medical Groups. Management has determined, based on the provisions of the MSAs between the Company and Non-Owned Medical Groups, and after considering the requirements of Accounting Standards Codification (“ASC”) Topic 810, Consolidation (“ASC 810”), the Company is not required to consolidate the financial position or results of operations of the Affiliated Practices associated with Owned Medical Groups; nor is it required to consolidate the financial position or results of operations of Non-Owned Medical Groups (and, therefore, the Company is not required to consolidate the Affiliated Practices of the Non-Owned Medical Groups). However, management has determined, based on the provisions of the Restriction Agreement on the Nominee Physician (“Friendly PC”), the governing documents of the Friendly Medical Groups, and after considering the requirements of ASC 810, that the Company should consolidate the financial position and results of operations of the Friendly Medical Groups and the Friendly PCs. ASC 810 requires the Company to consolidate the financial position, results of operations and cash flows of a Non-Owned Medical Group affiliated by means of a service agreement if the Non-Owned Medical Group is a VIE and the Company is its primary beneficiary. An Affiliated Practice would be considered a VIE if (a) it is thinly capitalized (i.e., the equity is not sufficient to fund the Non-Owned Medical Group’s activities without additional subordinated financial support) or (b) the equity holders of the Non-Owned Medical Group as a group have one of the following four characteristics: (i) lack the power to direct the activities that most significantly affect the Non-Owned Medical Group’s economic performance, (ii) possess non-substantive voting rights, (iii) lack the obligation to absorb the Non-Owned Medical Group’s expected losses, or (iv) lack the right to receive the Non-Owned Medical Group’s expected residual returns. The characteristics of both (a) and (b) do not exist and as such the Non-Owned Medical Groups do not represent VIEs. Accordingly, the Company has not consolidated the financial position, results of operations or cash flows of the Non-Owned Medical Groups that are affiliated with the Company by means of a service agreement for the three months ended June 30, 2026 and 2025. Each time that it enters into a new service agreement or enters into a material amendment to an existing service agreement, the Company considers whether the terms of that agreement or amendment would change the elements it considers in accordance with the VIE guidance. The same analysis was performed for the Affiliated Practices of Owned Medical Groups, which have contractual relationships with Privia through the SSA, and the Company determined they do not represent VIEs as they do not meet the criteria in ASC 810 for similar reasons as those outlined above. The Company, however, does meet the criteria for consolidation of the Nominee PCs and the Friendly Medical Groups based on the discussion above. Privia Medical Group – West Texas, PLLC, (“PMG West Texas”) is a physician-owned Medical Group, with PMG West Texas Holdings, PLLC (“Friendly WTX PC”), a Texas professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests and having governance and control rights via the governing documents of PMG West Texas. The Company has a contractual relationship with Friendly WTX PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (ii) and (iv) and, as such, PMG West Texas and Friendly WTX PC do represent VIEs and are consolidated as they do meet the criteria in ASC 810. Privia Medical Group Tennessee, PLLC (“PMG-TN”) is a physician-owned Medical Group, with PMG-TN Physicians, PLLC (“Friendly TN PC”), a Tennessee professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests therein and having governance and control rights via the governing documents of PMG-TN. Again, the same analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (ii) and (iv) and, as such, PMG-TN and Friendly TN PC do represent VIEs as they do meet the criteria in ASC 810. Privia Medical Group Washington, PLLC, (“PMG WA”) is a physician-owned Medical Group, with PMG Washington Holdings, PLLC (“Friendly WA PC”), a Washington professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests and having governance and control rights via the governing documents of PMG WA. The Company has a contractual relationship with Friendly WA PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG WA and Friendly WA PC do represent VIEs and are consolidated as they do meet the criteria in ASC 810. Privia Medical Group South Carolina, LLC, (“PMG SC”) is a physician-owned Medical Group, with PMG South Carolina Holdings, PLLC (“Friendly SC PC”), a South Carolina professional limited liability company entirely owned by a Nominee Physician, owning majority membership interests and having governance and control rights via the governing documents of PMG SC. The Company has a contractual relationship with Friendly SC PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG SC and Friendly SC PC represent VIEs and are consolidated as they meet the criteria in ASC 810. Privia Medical Group Indiana, LLC, (“PMG IN”) is a physician-owned Medical Group, with PMG Holdings Indiana, LLC, (“Friendly IN PC”), an Indiana professional limited liability company entirely owned by a licensed physician with a leadership role in the Company, owning majority membership interests and having governance and control rights via the governing documents of PMG IN. The Company has a contractual relationship with Friendly IN PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG IN and Friendly IN PC represent VIEs and are consolidated as they meet the criteria in ASC 810. Privia Medical Group Arizona, PLLC (“PMG-AZ”) is an Owned Medical Group, with the Company owning a majority of the membership interests and having governance and control rights through the governing documents of PMG-AZ. The VIE analysis was performed, and the Company determined that characteristic (a) exists, and, as such, PMG-AZ does represent a VIE and is consolidated as it does meet the criteria in ASC 810. Privia Medical Group New Jersey, LLC (“PMG-NJ”) is a physician-owned Medical Group, with PMGNJ Hold Co, P.C., (“Friendly NJ PC”), a New Jersey professional corporation entirely owned by a licensed physician with a leadership role in the Company, owning majority membership interests and having governance and control rights via the governing documents of PMG-NJ. The Company has a contractual relationship with Friendly NJ PC through a Restriction Agreement. The VIE analysis was performed, and the Company determined that characteristic (b) exists as a result of meeting (i), (ii) and (iv) and, as such, PMG-NJ and Friendly NJ PC represent VIEs and are consolidated as they meet the criteria in ASC 810.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. On an on-going basis, the Company evaluates significant estimates and assumptions, including, but not limited to, provider liability, revenue recognition, stock-based compensation, estimated useful lives of assets, intangible assets subject to amortization, the fair value of assets acquired and liabilities assumed in business combinations, and the provision for income taxes. These estimates are based on historical experience, current conditions, and other assumptions that management believes are reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are reviewed and updated as new information becomes available, additional experience is gained, future events occur, or the Company’s operating environment changes.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Pending Adoption	Recently Adopted Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes - Improvements to Income Tax Disclosures (“ASU 2023-09”). The amendments require (i) enhanced disclosures in connection with an entity’s effective tax rate reconciliation and (ii) income taxes paid disaggregated by jurisdiction. The amendment is effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 for the annual period ending December 31, 2025 on a prospective basis. In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in a Variable-Interest Entity. The amendment clarifies the guidance when an entity involved in an acquisition transaction effected primarily by exchanging equity interests and the legal acquiree is a VIE that meets the definition of a business. Entities must identify the accounting acquirer using the factors in ASC 805-10-55-12 through 55-15, rather than relying solely on the VIE consolidation model. The amendment is effective for annual reporting periods beginning after December 15, 2026, including interim periods within the fiscal years and applied prospectively to acquisitions after the adoption date. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements or related disclosures. Recently Issued Accounting Pronouncements Pending Adoption In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses (“DISE”) and in January 2025, issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure, which clarified the effective date of ASU 2024-03. The amendment requires disclosures about the nature of expenses included in the income statement, such as purchases of inventory, employee compensation and depreciation. The amendment is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact of ASU 2024-03 on its financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The amendment provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendment is effective for annual reporting periods beginning after December 15, 2027, including interim periods within the fiscal years, with early adoption permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-12, Codification Improvements (“Codification”), which addresses suggestions received from stakeholders on the Codification and makes other incremental improvements to GAAP. This evergreen project facilitates Codification updates for a broad range of topics arising from technical corrections, the unintended application of the Codification, clarifications, and other minor improvements. The amendment is effective for annual reporting periods beginning after December 15, 2026, including interim periods within the fiscal years, with early adoption permitted. The Company does not expect ASU 2025-12 to have a material impact on its financial statements and related disclosures.

Stockholders’ Equity - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 06, 2021	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares)		1,000,000,000		1,000,000,000		1,000,000,000
Share based payment expense		$ 19,396	$ 18,849	$ 41,317	$ 36,639
Unrecognized share-based compensation expense		$ 126,000		$ 126,000
Weighted-average period for recognition (in years)				1 year 2 months 12 days
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target period (in years)				3 years
Minimum \| Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target (as percent)				0.00%
Maximum \| Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of target (as percent)				200.00%
Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares)	10,278,581
Award percentage increase	5.00%
Options grant price percent of fair market value of company stock price (at least)	100.00%

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2026	Jul. 31, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	001-40365
Entity Registrant Name	Privia Health Group, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-3599420
Entity Address, Address Line One	950 N. Glebe Rd.,
Entity Address, Address Line Two	Suite 700
Entity Address, City or Town	Arlington,
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22203
City Area Code	571
Local Phone Number	366-8850
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	PRVA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		127,734,207
Entity Central Index Key	0001759655
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2026

Revenue Recognition - Schedule of Contract Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Revenue from Contract with Customer [Abstract]
Accounts receivable	$ 574,160	$ 400,902

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies There are no material commitments and contingencies as of June 30, 2026 and December 31, 2025. We are currently involved in, and may in the future become involved in, legal proceedings, claims, investigations and regulatory inquiries in the ordinary course of our business, including medical malpractice claims. These claims or proceedings can involve various types of parties, including governments, regulators, competitors, customers, partners, suppliers, service providers, licensees, licensors, employees, or stockholders, among others. Although the results of these legal proceedings, claims, investigations and inquiries cannot be predicted with certainty, we do not believe that the final outcome of any matters that we are currently involved in are reasonably likely to have a material adverse effect on our business, financial condition or results of operations. Regardless of final outcomes, however, any such proceedings, claims, inquiries and investigations may nonetheless impose a significant burden on management and employees and be costly to manage and defend, with potentially unfavorable preliminary or interim rulings. The Company records liabilities for its estimates of probable costs resulting from legal and regulatory matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: may involve indeterminate claims for monetary damages or may involve fines, penalties or civil damages; involve an uncertain number of potential claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in compliance practices. On March 24, 2026, after we made a voluntary disclosure to various federal and state authorities, the Company received a “Request for Information or Assistance” from the Department of Health and Human Services’ Office of Inspector General (“OIG”). The inquiry pertains to a single obstetric and gynecological Affiliated Practice that was formerly in Privia’s Mid-Atlantic service area, and whether that practice procured and implanted medical devices for a limited cohort of its patients without complying with applicable regulatory requirements. The Company is not aware of similar conduct at its other Affiliated Practices. The Company is cooperating with OIG’s request for information and is coordinating its response with the U.S. Department of Justice (“DOJ”) and the Commonwealth of Virginia’s Office of the Attorney General. While the Company does not currently believe that this matter is reasonably likely to have a material adverse effect on its business, financial condition or results of operations, the Company can provide no assurance as to the scope and outcome of this inquiry given its procedural status, including the ultimate extent of governmental interest in the matter.

Segment Financial Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
Segment Financial Information (Details) $ in Thousands	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) segment	Jun. 30, 2025 USD ($)
Segment Reporting [Line Items]
Number of operating segments \| segment			1
Number of reportable segments \| segment			1
Net income attributable to Privia Health Group, Inc. \| $	$ 9,048	$ 2,687	$ 12,112	$ 6,907
Single Operating Segment
Segment Reporting [Line Items]
Net income attributable to Privia Health Group, Inc. \| $	$ 9,000	$ 2,700	$ 12,100	$ 6,900

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2026
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company recorded a provision for income tax of $7.0 million and $2.5 million for the three months ended June 30, 2026 and 2025, respectively, and $12.6 million and $4.6 million for the six months ended June 30, 2026 and 2025, respectively. This represents an effective tax rate of 48.4% as of June 30, 2026 compared to 32.8% for the same period in the prior year. The effective tax rates differ from the statutory U.S. federal income tax rate of 21% primarily due to 162(m) limitations, state income taxes, and tax impacts related to equity award vesting and exercise events. The higher effective tax rate in the current quarter was primarily driven by unfavorable tax impacts related to equity award vesting and exercise events, as the associated tax deductions were lower than the related book compensation expense as well as the additional executives being subject to 162(m) limitations. Management considers both positive and negative evidence when evaluating the recoverability of our deferred tax assets (“DTAs”). The assessment is required to determine whether, based on all available evidence, it is more likely than not (i.e., greater than a 50% probability) that all or some portion of the DTAs will be realized in the future. As of June 30, 2026 and December 31, 2025, the weight of all available positive evidence was greater than the weight of all negative evidence, so a valuation allowance against the deferred tax asset was not recorded.

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 412,200	$ 479,685
Accounts receivable	574,160	400,902
Prepaid expenses and other current assets	38,906	30,414
Total current assets	1,025,266	911,001
Non-current assets:
Property and equipment, net	272	504
Right-of-use assets	8,038	8,794
Intangible assets, net	218,654	215,919
Goodwill	215,789	209,842
Deferred tax asset	0	2,274
Other non-current assets	20,562	21,044
Total non-current assets	463,315	458,377
Total assets	1,488,581	1,369,378
Current liabilities:
Accounts payable and accrued expenses	91,010	96,804
Provider liability	541,368	469,516
Operating lease liabilities, current	2,066	2,200
Total current liabilities	634,444	568,520
Non-current liabilities:
Operating lease liabilities, non-current	6,667	7,331
Deferred tax liability	3,737	0
Other non-current liabilities	5,660	2,584
Total non-current liabilities	16,064	9,915
Total liabilities	650,508	578,435
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.01 par value, 1,000,000,000 and 1,000,000,000 shares authorized; 126,289,983 and 123,604,576 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1,263	1,236
Additional paid-in capital	925,264	892,291
Accumulated deficit	(144,198)	(156,310)
Total Privia Health Group, Inc. stockholders’ equity	782,329	737,217
Non-controlling interest	55,744	53,726
Total stockholders’ equity	838,073	790,943
Total liabilities and stockholders’ equity	$ 1,488,581	$ 1,369,378

Segment Financial Information	6 Months Ended
Segment Financial Information	Jun. 30, 2026
Segment Reporting [Abstract]
Segment Financial Information	Segment Financial Information The Company determined in accordance with ASC Topic 280, Segment Reporting (“ASC 280”), that the Company operates in and reports as a single operating segment, which is to care for its patients’ needs. Operating segments are identified as components of an enterprise where separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, who reviews financial operating results on a regular basis for the purpose of allocating resources and evaluating financial performance. The Company defines its CODM as its Chief Executive Officer, who regularly reviews financial operating results on a consolidated basis for purposes of allocating resources and evaluating financial performance. Although the Company derives its revenues from a number of different geographic regions, the Company neither allocates resources based on the operating results from the individual regions, nor manages each individual region as a separate business unit. The Company’s CODM manages the operations on a consolidated basis to make decisions about overall corporate resource allocation and to assess overall corporate profitability. As of June 30, 2026 and December 31, 2025, all of the Company’s long-lived assets were located in the United States. The CODM uses consolidated net income attributable to Privia Health Group, Inc. to evaluate financial performance and allocate resources. Consolidated net income attributable to Privia Health Group, Inc. for the three months ended June 30, 2026 and 2025 was $9.0 million and $2.7 million, respectively, and $12.1 million and $6.9 million for the six months ended June 30, 2026 and 2025, respectively.

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	126,289,983	123,604,576
Common stock, shares outstanding (in shares)	126,289,983	123,604,576

Net Income Per Share - Schedule of Weighted-Average Anti-Dilutive Shares Outstanding Were Excluded From the Computation of Diluted Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Earnings Per Share [Abstract]
Weighted-average antidilutive shares outstanding (in shares)	4,116,262	4,931,666